Acylcarnitine Profile, Quantitative and Qualitative, Plasma

Test Code: AR
Turnaround time: 7 days (STAT: 1 day)
CPT Codes: 82017 x1

**Condition Description**

Plasma acylcarnitine profile by tandem mass spectrometer provides quantitative evaluations of individual acylcarnitine species in the plasma. Different patterns of the plasma acylcarnitine profile can indicate the diagnosis of fatty acid oxidation disorders (MCAD, VLCAD, SCAD, MAD, LCHAD, and CPTII), as well as some organic acidemias (propionic acidemia, methylmalonic acidemia, isovaleric acidemia, glutaric acidemia type I, 3-methylcrotonyl CoA carboxylase deficiency, B-ketothiolase deficiency, etc). If the above diseases are suspected, this analysis is recommended in conjunction with plasma amino acid analysis and urinary organic acid analysis. Plasma acylcarnitine values are compared to age-matched normal values.

**Indications**

This test is indicated for:

- Infants with a positive newborn screening result indicative of a metabolic disorder.
- Evaluation of patients with signs of a possible metabolic condition, such as lethargy, vomiting, and failure to thrive.
- Monitoring for individuals diagnosed with a metabolic condition.

**Methodology**

Electrospray Tandem Mass Spectrometry (MS/MS).

**Detection**

Test results should be interpreted in light of the patient's clinical and nutritional status.

**Reference Range**

Please [click here](#) for reference range.

**Specimen Requirements**

**Type: Plasma**

Specimen Requirements:

In sodium heparin (green top) tube: 1-2 ml

Sample should be collected while fasting or 2-4 hours postprandial.

Centrifuge to separate plasma and freeze.

Specimen Collection and Shipping: Ship frozen sample on dry ice with overnight delivery.

**Special Instructions**

Please indicate any medication or dietary changes on the test requisition.

**Related Tests**

- [Carnitine Concentration (CN) - Plasma](#) and [Organic Acid Analysis (OA) - Urine](#) are used in the diagnosis and evaluation of patients with organic acid or fatty acid disorders.

Disclaimer: This information is confidential and subject to change without notice. It may not be reproduced in whole or part unless authorized in writing by an authorized EGL representative.